Contract consultant and interim executive in life sciences commercial strategy, planning, and corporate development.
► Sample Engagements: Opportunity assessment of oncolytic viruses in breast and skin cancers. Global brand planning and lifecycle strategy for a leading, $4.6B dollar pharmaceutical in prostate cancer. Market planning and launch optimization strategies for liquid drug formulations in oncology, CV, and acute care in the hospital setting. Interim VP of Business Development for the launch of an AI driven platform of biopharma competitive intelligence insights (GlobalReach BI)
► Senior Advisor, Stealth Venture Fund. (life sciences all-stage venture capital fund) Assist and advise founders on deal sourcing, evaluation, structuring, due diligence, investment theses and Investment Committee reviews. Conduct commercial business, therapeutic, and financial due diligences, valuation, P&L and revenue model analysis, GTM strategy assessments, comparable and exit analyses.

Leadership team of a life sciences strategy practice advising biopharmaceutical clients broadly across commercialization and product planning, opportunity assessments / BD&L transactions, and portfolio development. Lead project delivery, client relationships, and team development.
► Sample Engagements: Partner search and engagement for out-licensing of early-stage COVID-19 mABs. Commercial due diligence for multiple assets in women's health, immunological disease, renal care, and oncology. Global product planning, TPP and label strategy, launch strategies, and expansive forecasts for two assets in inflammatory respiratory disease. U.S. market entry strategy for ex U.S. manufacturer of acute care saline IV hospital products. National IDN hospital engagement strategy for a specialty biopharma in respiratory. Commercial and corporate KPI development, dashboards, data warehousing, and rollout for midsized biopharma.

Directed client engagements throughout growth strategy and planning, investment evaluations / BD&L, launch planning, and commercial model innovation. Headed West coast practice development and team recruiting, plus national mentorship, training, and intern programs.
► Sample Engagements: Business and value chain DD for the acquisition of a CAR-T therapeutics company by a leading biopharma. Forecasting excellence and inventory management programs to improve working capital for a mid-size pharma client. Pipeline / portfolio strategy and market planning in numerous disease areas – including disease / market landscapes, TPP development, pricing, and forecasts. Commercial transformation, emerging markets strategy, and local growth enablement for a leading CV care company. Market scan, investment prioritization, and valuations for potential acquisition of multiple CV drug assets. Economic value assessment and pricing of a drug in maternal-fetal medicine. Portfolio strategy, global brand pla

Industry SME and engagement manager. Advised on clients' business model transformations, performance improvements, working capital efficiency, and go-to-market models. Developed new and existing client relationships, led generation of cross-firm proposals, created white papers, and represented firm in life sciences professional associations.
► Sample Engagements: Strategic options for the U.S. launch of a digital prescription monitoring device in respiratory care. Global commercial lifecycle strategy, forecasts, and scenario planning for a GI care pharmaceutical. Pricing and competitive strategy models for the launch of a biosimilar in renal care. Synergy assessment and global footprint evaluation for the integration of two pharmaceutical distributors. Adjacent markets growth strategies for a leading CRO / CDMO. Margin improvement of private-label products through co-sourcing and arbitrage opportunities for a major pharma distributor. Margin enhancement and reduced drug spend across g

Independent life sciences strategy consultant. Advisor and allied client partner to market access strategy firm Quorum Consulting.
► Sample Engagements: Licensing options, valuation, and market modeling for early-stage PCSK9 therapeutics. Global launch planning in ophthalmology – including market sizing, forecasting, pricing and market access strategy. HEOR economic cost / benefit modeling for multiple assets in biopharma, medtech, and diagnostics. Patient assistance program design for a drug launch in respiratory care.

Lead / Senior Manager, Cross-Portfolio Planning and Forecasting. Jan. 2008 – Jul. 2010 Senior Manager, Immunology Forecasting & Business Analysis. Aug. 2007 – Jan. 2008
Led the core of U.S. long-range strategic planning with defensible product development plans, forecasts, budgets, and risk scenarios. Provided high-impact cross-functional leadership and facilitation, ensuring rigorous analytics, collaboration, shared insights, and process excellence.
► Headed U.S. Business Plan Council, a senior cross-functional team of Brand, Finance, Development, and Supply partners directing the methodologies and processes of annual planning and forecasting for a ~$40B portfolio. Assured comprehensive, integrated planning methodologies. Assured cross-portfolio and "above the brand" alignment of assumptions, strategies, and initiatives. Delivered plans to executive audiences, and directed planning through a lengthy global merger driving top-level negotiations.
► Led forecasting and business analys

Spearheaded U.S. strategic planning and guided executive decision making and business performance reviews. Managed a pipeline of initiatives driving corporate development, commercial growth, portfolio development, and financial performance.
► As Secretary of the U.S. Executive Committee focused the C-Suite on strategic imperatives and follow-up. Managed and contributed to a priority agenda of projects, options, and operating requirements critical to commercial, financial, and organizational goals.
• Revamped processes of BD due diligence in the U.S. Co-led people and asset integration following two acquisitions.
• Advised on potential acquisitions and licensing deals predicted to deliver over 35% of future revenue and 40% of earnings.
► Led annual organization-wide long- and short-range strategic planning, in collaboration with senior cross-functional leaders. Introduced and embedded significant improvements with KPI / scorecard planning excellence and tools.